Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABP NASDAQ:ATHA NASDAQ:CTXR NASDAQ:EVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.26-6.7%$0.23$0.15▼$13.00$16.83M0.0323.56 million shs6.95 million shsATHAAthira Pharma$0.38+1.7%$0.35$0.22▼$3.67$14.54M3244,419 shs97,592 shsCTXRCitius Pharmaceuticals$1.28-5.2%$1.34$0.65▼$26.00$14.36M1.19672,288 shs201,557 shsEVAXEvaxion A/S$2.83+5.6%$2.61$1.20▼$17.75$3.76M0.13121,493 shs82,781 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro-6.68%-13.26%+38.26%+31.43%+25,839,900.00%ATHAAthira Pharma+1.74%+6.16%+14.81%+43.56%-87.97%CTXRCitius Pharmaceuticals-5.19%-7.91%-39.34%+85.24%-94.98%EVAXEvaxion A/S+5.60%+2.17%+23.04%+93.70%-79.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/AATHAAthira Pharma3.2468 of 5 stars3.05.00.00.01.13.31.3CTXRCitius Pharmaceuticals1.796 of 5 stars3.32.00.00.00.60.81.3EVAXEvaxion A/S1.8418 of 5 stars3.52.00.00.01.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,447.99% UpsideATHAAthira Pharma 2.00Hold$11.252,868.34% UpsideCTXRCitius Pharmaceuticals 2.50Moderate Buy$53.004,040.63% UpsideEVAXEvaxion A/S 3.00Buy$10.00253.36% UpsideCurrent Analyst Ratings BreakdownLatest EVAX, ABP, ATHA, and CTXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.006/9/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/23/2025CTXRCitius PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/23/2025CTXRCitius PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$180K87.27N/AN/A($0.29) per share-0.89ATHAAthira PharmaN/AN/AN/AN/A$1.16 per shareN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/A$10.25 per shareN/AEVAXEvaxion A/S$3.34M1.19N/AN/A($1.18) per share-2.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbpro-$7.23MN/A0.00∞N/AN/AN/A-198.95%N/AATHAAthira Pharma-$96.94M-$2.07N/AN/AN/AN/A-142.99%-106.40%8/7/2025 (Estimated)CTXRCitius Pharmaceuticals-$39.14MN/A0.001.02N/AN/A-58.63%-37.67%8/11/2025 (Estimated)EVAXEvaxion A/S-$10.57M-$1.16N/AN/AN/A-316.03%-532.72%-78.32%8/13/2025 (Estimated)Latest EVAX, ABP, ATHA, and CTXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025EVAXEvaxion A/S-$0.50N/AN/AN/AN/AN/A8/11/2025Q3 2025CTXRCitius Pharmaceuticals-$0.76N/AN/AN/A$1.92 millionN/A8/7/2025Q2 2025ATHAAthira Pharma-$0.18N/AN/AN/AN/AN/A5/27/2025Q1 2025EVAXEvaxion A/S-$0.65-$0.29+$0.36-$0.29$0.06 millionN/A5/15/2025N/AABPAbproN/A-$0.08N/A-$0.08N/AN/A5/14/2025Q2 2025CTXRCitius Pharmaceuticals-$1.08-$1.27-$0.19-$1.27N/AN/A5/9/2025Q1 2025ATHAAthira Pharma-$0.20-$0.23-$0.03-$0.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/AATHAAthira PharmaN/AN/AN/AN/AN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AEVAXEvaxion A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/A0.110.11ATHAAthira PharmaN/A7.267.26CTXRCitius PharmaceuticalsN/A0.370.06EVAXEvaxion A/SN/A2.012.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%ATHAAthira Pharma57.12%CTXRCitius Pharmaceuticals16.88%EVAXEvaxion A/S11.04%Insider OwnershipCompanyInsider OwnershipABPAbpro20.80%ATHAAthira Pharma22.10%CTXRCitius Pharmaceuticals10.70%EVAXEvaxion A/S41.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1560.79 million48.14 millionN/AATHAAthira Pharma4039.04 million30.41 millionOptionableCTXRCitius Pharmaceuticals2010.63 million9.50 millionOptionableEVAXEvaxion A/S601.40 million819,000No DataEVAX, ABP, ATHA, and CTXR HeadlinesRecent News About These CompaniesEvaxion A/S Announces Executive Changes to Boost AI-Immunology PlatformJuly 30, 2025 | theglobeandmail.comEvaxion to present two-year clinical efficacy data from Phase 2 EVX-01 trialJuly 25, 2025 | msn.comEvaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025July 25, 2025 | globenewswire.comEvaxion finalizes agreement with EIB to convert debt into equityJuly 11, 2025 | globenewswire.comEvaxion CEO Departs; CFO and Interim CEO AppointedJuly 1, 2025 | marketwatch.comEvaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolioJuly 1, 2025 | globenewswire.comEvaxion A/S Launches EVX-B4 Vaccine Development Program Targeting Group A Streptococcus InfectionsJune 27, 2025 | nasdaq.comEvaxion unveils new vaccine program to prevent group A Streptococcus infectionsJune 27, 2025 | bioworld.comBEvaxion A/S (EVAX) Income Statement - Yahoo FinanceJune 26, 2025 | finance.yahoo.comEVAX AI Technology Produces New Vaccine CandidateJune 25, 2025 | msn.comEvaxion expands R&D pipeline with new vaccine program targeting Group A StreptococcusJune 25, 2025 | globenewswire.comEvaxion Biotech Receives Grant Funding to Develop New Polio VaccineJune 4, 2025 | msn.comEvaxion receives grant funding to design new polio vaccineJune 3, 2025 | globenewswire.comEvaxion Biotech A/S (NASDAQ:EVAX) Q1 2025 Earnings Call TranscriptMay 29, 2025 | msn.comEvaxion Biotech’s Earnings Call Highlights Progress and ChallengesMay 29, 2025 | msn.comEvaxion Biotech Reports Q1 2025 Progress and FinancialsMay 27, 2025 | tipranks.comEvaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call TranscriptMay 27, 2025 | seekingalpha.comEvaxion Biotech: Evaxion announces business update and first quarter 2025 financial resultsMay 27, 2025 | finanznachrichten.deEvaxion announces business update and first quarter 2025 financial resultsMay 27, 2025 | globenewswire.comA Look at Evaxion Biotech's Upcoming Earnings ReportMay 26, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Super Micro Computer Sees Unusual Volume—Catalyst Ahead?By Gabriel Osorio-Mazilli | July 25, 2025View Super Micro Computer Sees Unusual Volume—Catalyst Ahead?This Drone Stock Is on Sale Despite Big Army ContractBy Jeffrey Neal Johnson | July 31, 2025View This Drone Stock Is on Sale Despite Big Army ContractThese 3 Undervalued Stocks Could Surge as Value Rotation NearsBy Gabriel Osorio-Mazilli | July 14, 2025View These 3 Undervalued Stocks Could Surge as Value Rotation NearsEVAX, ABP, ATHA, and CTXR Company DescriptionsAbpro NASDAQ:ABP$0.26 -0.02 (-6.68%) As of 08/6/2025 04:00 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Athira Pharma NASDAQ:ATHA$0.38 +0.01 (+1.74%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$0.34 -0.04 (-9.76%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Citius Pharmaceuticals NASDAQ:CTXR$1.28 -0.07 (-5.19%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$2.50 +1.22 (+95.31%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Evaxion A/S NASDAQ:EVAX$2.83 +0.15 (+5.60%) Closing price 08/6/2025 03:59 PM EasternExtended Trading$3.58 +0.75 (+26.50%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby Deal Gives Blade New Direction, But Stock Lacks Lift How DigitalOcean's Focus Is Fueling Explosive Growth Disney’s Iger-Led Turnaround Gains Traction Can Celsius Stock Keep Its Momentum Going Any Longer? AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
